Selling a specialist clinic group in the UK

You own a UK specialist clinic group worth between £5M and £50M in enterprise value. An aesthetic group with multi-site footprint and a strong brand. A fertility platform with established clinical results and a recognisable consultant team. An eye care or ophthalmology group. A dermatology platform. A specialist medical group in another defined sub-niche (pain, gastroenterology, women's health, men's health).

The buyer pool is segmented by sub-sector and well-funded across the board. PE-backed consolidators are active in every specialist clinic sub-segment, each with distinct strategies on geography, sub-sector and integration. Strategic acquirers include larger UK healthcare groups expanding their capability, and overseas strategics in fast-growing segments like aesthetics and fertility. The buyer composition for an aesthetic group looks very different from a fertility platform or an eye care chain.

We engage 12 to 24 months before a target exit. The longer window matters because the highest-return preparation work in specialist clinics — strengthening the brand and digital marketing engine, documenting clinical governance, addressing senior clinician retention, and (for aesthetics specifically) demonstrating sustainable customer acquisition economics — takes time.

This is not the right fit if your business is below £5M EV, or if CQC standing is in active remediation. In both cases the readiness phase is the place to start. It is also not the right fit if you are already committed to accepting a specific buyer's approach; that is a different mandate.

Buyer diligence in UK specialist clinic M&A is shaped equally by clinical and commercial factors. Six items dominate.

Brand and reputation first. In specialist clinics — particularly aesthetics, fertility and premium private care — brand carries more weight than in almost any other healthcare sub-sector. Strong digital presence, Trustpilot and Google review depth, senior clinician profile, and earned media all materially affect the headline multiple. Buyers value durable brand equity at a meaningful premium to commodity clinical capacity.

Clinical governance second. CQC standing, clinical audit framework, complications and outcomes data, and the depth of the clinical leadership structure. Outstanding CQC standing and a documented governance framework support stronger pricing and faster process. The opposite slows everything down.

Site economics third. Per-site EBITDA, average revenue per case, treatment-mix margin, and capacity utilisation. Multi-site groups where individual site performance varies widely are valued on the weaker sites.

Senior clinician retention fourth. Specialist consultants and clinical leadership materially affect both clinical results and brand. Buyers diligence tenure, billings, restrictive covenants, and post-sale lock-in arrangements carefully.

Patient acquisition economics fifth (especially in aesthetics). CAC by channel, conversion rate from enquiry to treatment, average patient LTV, treatment-mix profitability, and the trajectory of the marketing engine. Aesthetics businesses where unit economics are deteriorating despite headline growth trade poorly; those where unit economics are sustainable command premium pricing.

Payer mix and reimbursement sixth (especially in fertility, eye care and specialist medical). The mix between self-pay, insurer-funded, and NHS-contracted revenue, the trajectory of each, and the structural durability of insurer relationships. Diversified payer mix supports stronger multiples than single-payer dependency.

Our six-stage process runs senior-led from first conversation to completion. For specialist clinic groups, three things shape execution.

Brand and digital diligence sit alongside clinical and financial diligence. The buyer pack typically asks for digital marketing performance data, review trajectory, CAC benchmarks and brand sentiment alongside the clinical and financial data. We design the data room to anticipate this from the start, which keeps process momentum and avoids late-stage discovery.

Buyer mapping is segmented by sub-sector and increasingly international. UK consolidators form one pool. Overseas strategics in aesthetics and fertility form another and frequently pay differently. Our buyer mapping covers both, supported by our proprietary technology layer for surfacing acquirer signals from licensed market data.

Senior-led delivery matters because the conversations buyers want to have move between clinical, commercial, brand and operational at speed. Generic process management does not produce the trust required to walk a specialist clinic founder through to completion at premium pricing. See the healthcare services pillar for context and dental practices for an adjacent niche.